DALVANCE Drug Patent Profile
✉ Email this page to a colleague
When do Dalvance patents expire, and what generic alternatives are available?
Dalvance is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug.
This drug has fifty-eight patent family members in twenty countries.
The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Dalvance
Dalvance was eligible for patent challenges on May 23, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 23, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DALVANCE?
- What are the global sales for DALVANCE?
- What is Average Wholesale Price for DALVANCE?
Summary for DALVANCE
International Patents: | 58 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 6 |
Patent Applications: | 672 |
Drug Prices: | Drug price information for DALVANCE |
What excipients (inactive ingredients) are in DALVANCE? | DALVANCE excipients list |
DailyMed Link: | DALVANCE at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DALVANCE
Generic Entry Date for DALVANCE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for DALVANCE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Wake Forest University Health Sciences | Phase 4 |
University of Colorado, Denver | Phase 2/Phase 3 |
Washington University School of Medicine | Phase 4 |
Pharmacology for DALVANCE
Drug Class | Lipoglycopeptide Antibacterial |
US Patents and Regulatory Information for DALVANCE
DALVANCE is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of DALVANCE is ⤷ Try for Free.
This potential generic entry date is based on patent 6,900,175.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | RX | Yes | Yes | 6,900,175 | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DALVANCE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | 8,143,212 | ⤷ Try for Free |
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | 7,115,564 | ⤷ Try for Free |
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | 7,119,061 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DALVANCE
See the table below for patents covering DALVANCE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2005119206 | СПОСОБЫ ВВЕДЕНИЯ ДАЛБАВАНЦИНА ДЛЯ ЛЕЧЕНИЯ БАКТЕРИАЛЬНЫХ ИНФЕКЦИЙ | ⤷ Try for Free |
Russian Federation | 2333766 | СПОСОБЫ ВВЕДЕНИЯ ДАЛБАВАНЦИНА ДЛЯ ЛЕЧЕНИЯ БАКТЕРИАЛЬНЫХ ИНФЕКЦИЙ (METHODS OF DALBAVANCIN ADMINISTRATION FOR TREATMENT OF BACTERIAL INFECTION) | ⤷ Try for Free |
South Korea | 100930982 | ⤷ Try for Free | |
Portugal | 1565201 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Dalbavancin Market Dynamics and Financial Trajectory
More… ↓